Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.

Jon O. Ebbert, Kirk D. Wyatt, Ali Zirakzadeh, Michael V. Burke, J. Hays

Research output: Contribution to journalReview article

4 Scopus citations

Abstract

Chronic obstructive pulmonary disease (COPD) is a costly and deadly disease afflicting an estimated 210 million people and accounting for 5% of all global deaths. Exposure to cigarette smoke is the greatest risk factor for COPD in the developed world. Smoking cessation improves respiratory symptoms and lung function and reduces mortality among patients with COPD. Cigarette smokers with COPD and other co-morbid conditions such as cardiovascular disease and psychiatric illnesses should receive comprehensive tobacco treatment interventions incorporating efficacious pharmacotherapies. Varenicline, an alpha(4)beta(2) nicotinic acetylcholine receptor partial agonist, is the newest and most effective drug currently available to promote smoking cessation. In conjunction with behavioral interventions and clinical monitoring for potential side effects, varenicline offers great hope for reducing smoking-attributable death and disability.

Original languageEnglish (US)
Pages (from-to)421-430
Number of pages10
JournalInternational journal of chronic obstructive pulmonary disease
Volume4
DOIs
StatePublished - 2009

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Health Policy
  • Public Health, Environmental and Occupational Health

Fingerprint Dive into the research topics of 'Clinical utility of varenicline for smokers with medical and psychiatric comorbidity.'. Together they form a unique fingerprint.

  • Cite this